Oak Bay Biosciences is a new biotechnology company – with a portfolio of patents, molecules, and preclinical data – with the goal to bring the first therapy for Stargardt disease to market. Stargardt disease affects approximately 800,000 individuals worldwide and causes progressive, irreversible blindness – often beginning in childhood. Oak Bay Biosciences' lead molecule could prevent blindness for the lifetime of a patient due to high potency, durability, and extended half-life in the eye.